310.45 -5.11 (-1.65%) Buy

Don't consider buying JBCHEPHARM now, it is risky at the moment

13 min read

J B CHEMICALS AND PHARMA delivered massive losses today. It lost -1.65% to close at 310.45. It's recent 5 day performance has been -1.14%, +1.12%, +4.8%, +0.28% and -0.07%.

[Themes containing JBCHEPHARM]

JBCHEPHARM showed a up trend over the last 3 months. During this period JBCHEPHARM grew by +1.95% and saw a maximum drawdown of -7.93%. It has been unusually choppy during this period. Long term investors are better off avoiding investing in JBCHEPHARM till volatility reduces and a clear trend emerges.


JBCHEPHARM has been outperforming the NIFTY-50 index in recent time. Over the last 3 years and 1 month, JBCHEPHARM underperformed the NIFTY-50 index on 53% days.

During the last three months JBCHEPHARM delivered losses on 56% days. However, it still managed to end this period in a profit. It's best return during this period (of +4.8%) was on Tuesday, 15 Jan, 2019. While it's worst loss in the same period (of -2.43%) was on Monday, 22 Oct, 2018. There was initially a bearish trend during this period which started on 20 Nov, 2018 and went on till 26 Nov, 2018. The trend delivered -4.28% losses to investors. This was followed by a bullish trend that started on 27 Dec, 2018 and ended on 3 Jan, 2019. This bullish trend delivered +5.55% to investors.

JBCHEPHARM had 7 profitable and 5 loss making months over the last year. JBCHEPHARM was profitable in more months than NIFTY-50 index. JBCHEPHARM significantly outperformed NIFTY-50 index in Aug 2018, when it returned +25.64% compared to +6.56% returned by NIFTY-50 index during it's best month in the last one year - Jul 2018. JBCHEPHARM and NIFTY-50 index, both had periods of 2 consecutive profitable months. It is interesting to note that both JBCHEPHARM and NIFTY-50 index significantly outperform during months when quarterly/annual results are announced.

It is time for us to stand and cheer for the doer, the achiever, the one who recognizes the challenge and does something about it.
-- Vince Lombardi

JBCHEPHARM is becoming more volatile overall. In comparison, the NIFTY-50 index is seeing a fall in volatility. During the last three months, there was a significant fall in JBCHEPHARM's volatility from 19 Oct, 2018 to 26 Nov, 2018. While there was a significant fall in the NIFTY-50 index's volatility from 31 Oct, 2018 to 5 Dec, 2018.

Advanced/professional short-term investors should note that JBCHEPHARM has significant negative skewness in it's return distribution. This indicates that JBCHEPHARM is very risky for short-term investment and can significantly underperform for long durations.

NIFTY-50 index has more chance of extreme outcomes than JBCHEPHARM. Therefore, NIFTY-50 must receive a lower allocation than JBCHEPHARM in your portfolio. NIFTY-50 index usually has shorter drawdown period than JBCHEPHARM.

On a general note (since you are interested in JBCHEPHARM), TORNTPHARM is a large cap that deserves to be closely tracked for investment opportunities.

Want to improve your Portfolio's performance?

Spotalpha's Portfolio optimizer is all you need to improve your returns and reduce your risk.
Optimize Portfolio NOW
If you liked what you read here ...

... we have a small favour to ask. Help us bring the power of algorithmic trading strategies to individual investors.

All content in this article was automatically generated by algorithms. This ensures that there are no human biases in the analysis provided. This approach to investing is not new and has been around for more than three decades. Yet, it has been available to only the most affluent or elite investors leaving individual investors to trade on emotions (such as fear and greed), intuition and poor analysis from third-parties. We want to change this.

We want to empower investors with all the tools and analysis required by them to make a rational investment decision.

If you found Spotalpha useful, consider making a contribution. For as little as $5 you can support our efforts and it takes less than a minute. Thank you. Contribute
Share with friends   WhatsApp   Facebook   Twitter